Maas Biolab is a private biotechnology firm focused on developing a neuropharmaceutical drug to treat chronic neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer's, Parkinson's, and Huntington's. The company holds formulation and production patents for cyclosporins as neuroprotective agents and has received FDA Orphan Drug Designation for cyclosporin in the treatment of ALS. Their goal is to provide healthcare practitioners with advanced drugs for improved treatment outcomes.